Vivos Therapeutics, Inc. entered into an Exchange Agreement with Streeterville Capital, LLC to exchange debt for equity, and also entered into a $5,000,000 convertible promissory note with V-Co Investors 4 LLC. Additionally, the company is currently not in compliance with Nasdaq's minimum bid price requirement of $1.00 per share and the minimum stockholders' equity requirement.
